Santhera and ReveraGen Announce Positive and Statistically Highly Significant Topline Results with Vamorolone in Pivotal VISION-DMD Study

NEXT STORY
Polyphor’s Balixafortide Demonstrates Consistent Dual Action Anti-Viral and Anti-Inflammatory Activity in COVID-19 Preclinical Trials
PREV STORY
Scopus BioPharma Announces New Date for 2021 Annual Meeting of Stockholders
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology

ROCKVILLE, Md., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a ...

author_avatar
NASDAQ Market News

CytomX to Present at the Cantor Fitzgerald Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), ...

author_avatar
NASDAQ Market News

Eurobio Scientific reaches the €50m sales mark in 2018

EUROBIO SCIENTIFIC REACHES THE €50M SALES MARK IN 2018 Eurobio Scientific consolidated sales reached ...

author_avatar
NASDAQ Market News